PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements In Chloride Channel Function In Cystic Fibrosis Patients
PTC Therapeutics, Inc. (PTC) announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle SermetGaudelus, M.D., Ph.D.
More: continued here
Filed under: Clinical Trials on October 27th, 2008